Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
ACADEMIA
Scientific Societies Propose Measures for Osteoporosis Treatment amid Shortages of Vitamin D Analogs
In the wake of a series of shipment restrictions on active vitamin D3 analogs, Japanese scientific societies issued a proposal on July 19, calling on doctors to address their shortages by avoiding switching from eldecalcitol to alfacalcidol in the treatment…
To read the full story
Related Article
- Chugai Lifts Shipment Curbs for Edirol, Easing Active Vitamin D3 Shortages
September 13, 2021
- Osteoporosis Society Greatly Alarmed by Vitamin D3 Analog Shortages, Might Take Further Measures
July 29, 2021
- Prioritize Alfacalcidol Supply for Non-Osteoporosis Indications: MHLW
July 27, 2021
- Kyowa Suspending Alfacalcidol Supply; Chugai Curbs Further Products
July 21, 2021
- Kyosomirai Controls Shipments for Generic Calcitriol Amid Vitamin D3 Preparation Shortage
July 20, 2021
- Teijin Restricting Shipments for Onealfa after Curbs on Edirol
July 13, 2021
- Edirol, Generic Drugs All Now Face Supply Curbs as Nichi-Iko Woes Spill Over
July 8, 2021
- Nichi-Iko Halts Supplies of Some Edirol Generic Products, Re-Supply Expected for September
June 22, 2021
ACADEMIA
- Emergency Approval Push for Shionogi’s COVID Pill Not Profit-Driven: Academic Societies
September 9, 2022
- University of Tokyo to Open Pathogen Research Facility to Drug Makers, CROs to Accelerate Vaccine Development
September 8, 2022
- Academic Societies Urge Japan Govt to Approve Shionogi’s COVID-19 Pill
September 5, 2022
- Japanese Society of Formulary to Support Regional Initiatives: President
August 18, 2022
- Japan Pediatric Society Recommends COVID Jab for Ages 5-17
August 12, 2022
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…